Granulomatosis with Polyangiitis of Sinonasal Tract

Abstract
Granulomatosis with polyangiitis also known as Wegener’s Granulomatosis is a granulomatous disease which involves multiple organs as upper and lower respiratory tract, nasal, sinuses, kidneys, parotids are few of them. It is of two types - limited and systemic. Limited type is difficult to diagnose and commonly involves ENT organs as nose, ear and sinuses. ENT involvement as the presentation as the first symptom of the disease ranges from 63% and 72% of cases of patients. This review will thus focus on the sinonasal involvement in granulomatosis with polyangiitis.

Abbreviations: GPA: Granulomatosis with Polyangiitis; WG: Wegener’s Granulomatosis; ANCA: Anti-Neutrophil Cytoplasmic Antibody

Introduction
Granulomatosis with polyangiitis (GPA) also known as Wegener’s granulomatosis (WG) was first identified as a clinical entity by Friedrich Wegener in 1936. It is a granulomatous disease which involves multiple organs. It involves progressive ulceration in the respiratory tract along with signs of widespread inflammatory disease, histological examination show granulomas, frequently in the respiratory tract and kidneys [1,2].

GPA is an autoimmune disorder of unknown cause, characterised by necrotising granulomatous inflammatory and pauci-immune vasculitis in small and medium sized blood vessels (capillaries, venules, arterioles and arteries). It primarily affects upper and lower respiratory tract and the kidneys with segmental necrotising glomerulonephritis. Organ systems which can also be affected, include nose, paranasal sinuses, eyes, ears, skin, joints, bones, salivary glands, thyroid, heart, liver, colon and intestine [3,4].

WG can manifest as two forms: limited disease and generalised disease with renal involvement. Limited variety can involve upper respiratory tract with only involvement of sinonasal tract. A delay in its confirmation and start of treatment may lead to varied complications. So early diagnosis is very important thus particular emphasis on sinonasal involvement is needed.

Epidemiology
The prevalence of WG ranges between 3 cases per 100 000 (USA) to 16 cases per 100 000 (southern Sweden) [5]. The most common age of presentation of WG is the sixth and seventh decades, but it can appear at any age [6]. The presence of ENT involvement in patients with WG ranges between 72.3% and 99% [7,8]. ENT involvement and presentation as the first symptom of the disease ranges from 63% and 72% of cases [9,10].

Pathology
Histopathologic findings in WG vary with location and type of involvement in the respiratory tract. In sinonasal disease histopathologic examination of nasal and sinus tissue involved frequently reveals extensive tissue necrosis and infiltration with mixed population of inflammatory cells or occasionally necrotising granulomas. Histopathologic findings of vasculitis are not often seen in pathologic specimens from upper respiratory tract [11,12].

Clinical manifestations
Patients with GPA (either classic or limited) may have either upper airway or pulmonary involvement and simultaneous involvement of both may also be seen. They may present with nonspecific or systemic complaints of fever, anorexia, weight loss, and malaise [13].

Nasal and sinus disease are the most common presenting symptoms and signs of GPA. It includes- nasal crusting, sinus pain, chronic rhinosinusitis, nasal obstruction, olfactory disturbances, purulent or bloody nasal discharge, excessive tearing (epiphora) and formation of sinus mucocele (benign, epithelium-lined cysts filled with mucus). Nasal congestion and purulent nasal discharge fails to resolve with appropriate antibiotic therapy. There may be perforation of nasal septum, saddle nose deformity, serous otitis, and hearing loss [14,15]. Adjacent structures such as orbital pseudo tumor with proptosis and vision impairment, oral ulcers may also get affected [16].

Laboratory findings
For patients with nasal ulcerations or a saddle nose deformity, cocaine addiction should also be considered.
Hematologic abnormalities in GPA includes a leukocytosis, thrombocytosis (>400,000/mm3), and elevation of the erythrocyte sedimentation rate [17]. The plasma creatinine and urinalysis are normal in sinonasal GPA.

Generally, in patients with sinonasal GPA involvement have normal ANCAs levels in the serum.

**Imaging**

**Sinus computed tomography**

Multi planar sinus CT scan is the preferred imaging modality for evaluating chronic rhinosinusitis and suspected rhino sinus involvement by WG [18,19]. Common findings on sinus CT are mucosal thickening in the nasal cavity and paranasal sinuses, bony destruction of the nasal cavity and paranasal sinuses, and bony thickening of the paranasal sinuses.

**Nasal or sinus biopsy**

Nasal and sinus biopsies are performed for evaluation and treatment of nasal obstruction due to soft tissue masses and chronic sinusitis [14,20]. Special stains and culture should also be sent for ruling out infections as fungal, mycobacterial. Histopathological infection should also be done.

Patients with limited or sinonasal GPA would not fulfill the American college of Rheumatology criteria 1990 classification criteria for GPA. So a high suspicion and regular follow up should be done to look for other organ involvement (Table 1).

**Differential Diagnosis of Destructive Lesions of Sinonasal Tracts**

I. Trauma: Accidental or self-induced (Rhinotillexomania).

II. Infection

i. Bacterial: mycobacteria, syphilis, leprosy, actinomycosis.

ii. Fungal: aspergillosis, rhino mucormycosis.

III. Toxic substance: Cocaine abuse [21], Chromium salts.

IV. Inflammatory: Sarcoidosis, foreign-body granuloma, wegener’s granulomatosis, polyarteritis nodosa.

V. Neoplastic: Basal cell carcinoma, squamous cell carcinoma, rhabdomyosarcoma, lymphoma.

**Treatment**

In general, limited or sinonasal manifestations of patients with GPA usually respond well to immunosuppressive therapy (methotrexate or cyclophosphamide) along with tapering glucocorticoids. Maintenance therapy with methotrexate and azathioprine is useful. Frequent boluses of glucocorticoids to control reactivations can be used when required. Refractory disease may be treated with rituximab -anti CD20 monoclonal antibody [22].

Surgical treatment does not change the course of the disease. It can ameliorate the consequences of tissue destruction in the head and neck region. Surgery should be done when the disease is under remission.

**Conclusion**

Patients with GPA often present sinonasal manifestations. It is important to perform a systematic and ENT exploration of patients with suspected or confirmed diagnosis of GPA in order to contribute to an early diagnosis of these manifestations so as to prevent secondary complications which would worsen the quality of life of these patients.

**References**

1. Walton EW (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2(5091): 265-270.

2. Renaudineau Y, Le Meur Y (2008) Renal involvement in Wegener's granulo-matosis. Clin Rev Allergy Immunol 35(1-2): 22-29.

3. Figueiredo S, Leal LM, Morais A, Magalhães A, Oliveira T, et al. (2009) Wegener granulomatosis-otologic, nasal, tracheobronchial
Granulomatosis with Polyangiitis of Sinonasal Tract

4. Bali M, Aydemir S, Arinosy T, Sindel Š, Memiş L (1997) An unusual case of Wegener’s granulomatosis. Nephron 76(2): 237-238.

5. Mohammad AJ, Jacobsson UT, Mahr AD, Sturfelt G, Segelmark M (2007) Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 46(8): 1329-1337.

6. Gonzalez-Gay MA, Garcia-Porrua C (2001) Epidemiology of the vasculitides. Rheum Dis Clin North Am 27(4): 729-749.

7. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, et al. (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43(5): 1021-1032.

8. McDonald TJ, DeRemee RA (1993) Head and neck involvement in Wegener’s granulomatosis. In: Gross WL (Eds.), ANCA associated systemic vasculitis: immunological and clinical aspects. Plenum Press, New York, USA, pp: 309-313.

9. Srouji IA, Andrews P, Edwards C, Lund VJ (2007) Patterns of presentation and diagnosis of patients with Wegener’s Granulomatosis. ENT aspects. J Laryngol Otol 121(7): 653-658.

10. Erickson VR, Hwang PH (2007) Wegener’s granulomatosis: current trends in diagnosis and management. Curr Opin Otolaryngol Head Neck Surg 15(3): 170-176.

11. Yousem SA (2005) Wegener’s granulomatosis. In: Churg AM et al. (Eds.), Thurbeck’s Pathology of the Lung, (3rd edn), Thieme, New York, USA, pp: 371.

12. Maguchi S, Fukuda S, Takizawa M (2001) Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener’s granulomatosis. Auris Nasus Larynx 28: S53-S58.

13. Specks U (2011) Pulmonary vasculitis. In: Schwarz et al. (Eds.), Interstitial Lung Disease, (5th edn), People’s Medical Publishing House, Shelton, USA, pp: 765.

14. Polychronopoulos VS, Prakash UB, Golbin JM, Edell ES, Specks U (2007) Airway involvement in Wegener’s granulomatosis. Rheum Dis Clin North Am 33(4): 755-775.

15. Cannady SB, Batra PS, Koenig C, Koenig C, Lorenz RR, Citardi MJ, et al. (2009) Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 119(4): 757-761.

16. Solans-Laque R, Bosch-Gil J, Canela M, Lorente J, Pallisa E, et al. (2008) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Lupus 17(9): 832-836.

17. Hoffman GS, Kerr GS, Lervitt RV, Hallahan CW, Lebovics RS, et al. (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116(6): 486-498.

18. Lohmann C, Uhl M, Warnatz K, Kotter E, Ghanem N, et al. (2006) Sinonasal computed tomography in patients with Wegener’s granulomatosis. J Comput Assist Tomogr 30(1): 122-125.

19. Silversa S, Vignaux O, Legmann P (2007) Sinonasal and cerebral imaging findings in Wegener’s granulomatosis. Presse Med 36(5): 913-921.

20. Borner U, Landis BN, Banz Y, Villiger P, Ballinari P, et al. (2012) Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy 26(6): 477-480.

21. Raffalovich SM, Kelly PD (2008) Cocaine-induced midline destructive lesions mimicking ENT-limited Wegener’s granulomatosis. Scand J Rheumatol 37(6): 477-480.

22. Holle JU, Dubravc H, Herlyn K, Heller M, Ambrosch P, et al. (2012) Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatosis versus vasculitic manifestations. Ann Rheum Dis 71(3): 327-333